Respiratory syncytial virus infections Trials in Rochester, United States
Conditions / Respiratory syncytial virus infections / Rochester, United States
Respiratory syncytial virus infections has been the subject of sustained clinical investigation across multiple research sites.
15 total trials for this combination
Showing top 10 of 15 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00384462 | Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature Infants | COMPLETED | — |
| NCT04732871 | Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03814590 | A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults | COMPLETED | PHASE1/PHASE2 |
| NCT06534892 | An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT02325791 | Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants | COMPLETED | PHASE3 |
| NCT06389487 | A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above | COMPLETED | PHASE3 |
| NCT02202356 | A Study of ALS-008176 in Infants Hospitalized With RSV | COMPLETED | PHASE1 |
| NCT04886596 | Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above | COMPLETED | PHASE3 |
| NCT05238025 | MVA-BN-RSV Vaccine Trial | TERMINATED | PHASE3 |
| NCT00129766 | Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children | COMPLETED | PHASE3 |